跳至主要内容
临床试验/ACTRN12616000281493
ACTRN12616000281493已完成不适用

The use of simultaneous EEG and fMRI to monitor the effects of ketamine and midazolam on brain activity in healthy adult males

The University of Auckland0 个研究点目标入组 30 人开始时间: 2016年3月3日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 45 Years(—)
性别
Male

入选标准

  • *Participant is willing and able to give informed consent for participation in the study
  • *In the Investigators’ opinion, is able and willing to comply with all study requirements

排除标准

  • *Cardiovascular conditions including abnormal heart rate and blood pressure checked at screening.
  • *Participants who have participated in another research study involving an investigational product in the past 12 weeks.
  • *History of psychosis or personality disorder.
  • *Any unstable medical or neurologic condition.
  • *Substance abuse or dependence in previous 6 months.
  • *Any history of abuse of ketamine or benzodiazepenes.
  • *Contraindication to the use of ketamine/midazolam according to manufacturer guidelines.
  • *Body-weight <50kg or >120kg.
  • *BMI <18.5 or > 30
  • * Failure of the Health Questionnaire section of the Anaesthesia assessment patient questionnaire”.
  • *Any other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the study.
  • *Regular use of any medication deemed to be contraindicating as judged by the attending study physicians (e.g. benzodiazepenes / sedatives / sleeping agents / NMDA antagonists).
  • *Inability to speak or read English.
  • *Contraindications for MRI scanning
  • *Needle phobia
  • *History of claustrophobia

研究者

相似试验